Skip to content 
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. more
| Time Frame | PBM | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | -1.28% | -1.08% | -1.38% |
| 1-Month Return | -36.82% | -0.47% | -1.81% |
| 3-Month Return | -82.28% | 2.13% | 1.38% |
| 6-Month Return | -84.65% | 17.04% | 5.68% |
| 1-Year Return | -95.15% | 6.56% | 11.74% |
| 3-Year Return | -99.99% | 16.78% | 65.15% |
| 5-Year Return | -99.99% | 34.34% | 73.68% |
| Mar '22 | Mar '23 | Mar '24 | Mar '25 | |||
|---|---|---|---|---|---|---|
| Total Revenue | - | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] | |
| Cost of Revenue | - | - | 240.00 | 4.27K | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":5.62,"profit":true},{"date":"2025-03-31","value":100,"profit":true}] | |
| Gross Profit | - | - | (240.00) | (4.27K) | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":-24000,"profit":false},{"date":"2025-03-31","value":-426800,"profit":false}] | |
| Gross Margin | - | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] | |
| Operating Expenses | 334.29K | 1.29M | 2.75M | 3.66M | [{"date":"2022-03-31","value":9.14,"profit":true},{"date":"2023-03-31","value":35.37,"profit":true},{"date":"2024-03-31","value":75.21,"profit":true},{"date":"2025-03-31","value":100,"profit":true}] | |
| Operating Income | (334.29K) | (1.29M) | (2.75M) | (3.66M) | [{"date":"2022-03-31","value":-33429000,"profit":false},{"date":"2023-03-31","value":-129398000,"profit":false},{"date":"2024-03-31","value":-275182500,"profit":false},{"date":"2025-03-31","value":-366302300,"profit":false}] | |
| Total Non-Operating Income/Expense | 8.56M | 9.31M | (48.46M) | 4.76M | [{"date":"2022-03-31","value":92,"profit":true},{"date":"2023-03-31","value":100,"profit":true},{"date":"2024-03-31","value":-520.5,"profit":false},{"date":"2025-03-31","value":51.14,"profit":true}] | |
| Pre-Tax Income | 8.23M | 8.01M | (51.16M) | 1.01M | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":97.37,"profit":true},{"date":"2024-03-31","value":-621.58,"profit":false},{"date":"2025-03-31","value":12.29,"profit":true}] | |
| Income Taxes | - | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] | |
| Income After Taxes | - | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] | |
| Income From Continuous Operations | (1.86M) | (3.21M) | (51.16M) | 1.01M | [{"date":"2022-03-31","value":-183.66,"profit":false},{"date":"2023-03-31","value":-316.9,"profit":false},{"date":"2024-03-31","value":-5056.29,"profit":false},{"date":"2025-03-31","value":100,"profit":true}] | |
| Income From Discontinued Operations | - | - | - | - | [{"date":"2022-03-31","value":"-","profit":true},{"date":"2023-03-31","value":"-","profit":true},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":"-","profit":true}] | |
| Net Income | 8.23M | 8.01M | (51.16M) | 1.01M | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":97.37,"profit":true},{"date":"2024-03-31","value":-621.58,"profit":false},{"date":"2025-03-31","value":12.29,"profit":true}] | |
| EPS (Diluted) | 950.63 | (7.85) | - | (414.17) | [{"date":"2022-03-31","value":100,"profit":true},{"date":"2023-03-31","value":-0.83,"profit":false},{"date":"2024-03-31","value":"-","profit":true},{"date":"2025-03-31","value":-43.57,"profit":false}] | |
These ratios help you determine the liquidity of the company. Higher is better.
| PBM | |
|---|---|
| Cash Ratio | 7.63 |
| Current Ratio | 8.09 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| PBM | |
|---|---|
| ROA (LTM) | -34.44% |
| ROE (LTM) | -74.29% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| PBM | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.07 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.93 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| PBM | |
|---|---|
| Trailing PE | NM |
| Forward PE | NM |
| P/S (TTM) | 0.00 |
| P/B | 0.26 |
| EV/R | 0.00 |
| EV/Ebitda | 1.31 |
Psyence Biomedical Ltd. Common Shares (PBM) share price today is $3.09
Yes, Indians can buy shares of Psyence Biomedical Ltd. Common Shares (PBM) on Vested. To buy
Yes, you can purchase fractional shares of Psyence Biomedical Ltd. Common Shares (PBM) via the Vested app. You can start investing in Psyence Biomedical Ltd. Common Shares (PBM) with a minimum investment of $1.
You can invest in shares of Psyence Biomedical Ltd. Common Shares (PBM) via Vested in three simple steps:
The 52-week high price of Psyence Biomedical Ltd. Common Shares (PBM) is $74.94. The 52-week low price of Psyence Biomedical Ltd. Common Shares (PBM) is $2.54.
The price-to-earnings (P/E) ratio of Psyence Biomedical Ltd. Common Shares (PBM) is
The price-to-book (P/B) ratio of Psyence Biomedical Ltd. Common Shares (PBM) is 0.26
The dividend yield of Psyence Biomedical Ltd. Common Shares (PBM) is 0.00%
The market capitalization of Psyence Biomedical Ltd. Common Shares (PBM) is $2.87M
The stock symbol (or ticker) of Psyence Biomedical Ltd. Common Shares is PBM
Consider the share price of Psyence Biomedical Ltd. Common Shares as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Psyence Biomedical Ltd. Common Shares has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.
When investing in Psyence Biomedical Ltd. Common Shares shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Psyence Biomedical Ltd. Common Shares stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.
Rather than merely checking the share price of Psyence Biomedical Ltd. Common Shares and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Psyence Biomedical Ltd. Common Shares stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.
Link copied 
